Automated, High Purity Cell Isolation for Efficient Cell Therapy Manufacturing

Webinar On-Demand - Automated, High Purity Cell Isolation for Efficient Cell Therapy Manufacturing

In cell therapy applications, commonly employed cell purification platforms for large-scale isolation of immune or stem cells separate cells based on a single cell surface antigen. Enrichment based on multiple cell surface markers or different expression levels of these markers often requires the use of a traditional cell sorter. This webinar describes the CGX10 Cell Isolation System from Sony Biotechnology, a fully closed, automated system suitable for clinical grade, GMP-compliant cell sorting. The system utilizes a novel microfluidics technology to achieve high purity cell isolation within a closed and sterile microfluidics chip.

In this webinar, we will deliver a virtual demo of the CGX10 system’s capabilities, including advanced automation, innovative software with an intuitive user interface, built-in 21 CFR Part 11 compliance features, and purpose-built consumable installation. We will also discuss the CGX10’s role in advancing next-gen cell therapies such as CAR-T, CAR-Treg, and stem cell based therapies.

Learning Objectives:

Who should attend

This webinar will be of interest to cell therapy specialists, clinical scientists, and production engineers working in cell and gene therapy manufacturing at the research, process development, or GMP production stage. Professionals involved in developing workflows for wide range of cell therapy modalities, including CAR-T, Treg, TIL-based, CAR-NK and other immune cell therapies, and stem cell–based therapies, would benefit from this webinar.

Watch Now

Speaker

Portrait of Aditi Singh, PhD

Aditi Singh, PhD
Global Senior Product & Marketing Manager
Sony Biotechnology Inc.

Aditi leads the launch, commercialization, and management of instruments used in the clinical-grade cell and gene therapy manufacturing workflow. Her goal has been to improve the accessibility of cancer immunotherapies and precision medicines for patients. Aditi has a PhD in cell and molecular biology from the University of Heidelberg, Germany, and post-doctoral experience from the University of California, San Diego, where she worked in the fields of infectious diseases and mRNA biology.